Stay updated on ABP 798 vs. Rituximab in RA Clinical Trial
Sign up to get notified when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.

Latest updates to the ABP 798 vs. Rituximab in RA Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page’s footer/update metadata was bumped to a new revision version (v3.5.3 instead of v3.5.2), reflecting a technical site/version change without modifying the listed study information.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedRevision: v3.5.0 deployed to replace v3.4.3. No substantive changes to the study details, eligibility criteria, or results are reflected on the page.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 to reflect a new page version. No study details were changed.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision: v3.4.2 is now shown as the site version, and the previous government funding lapse notice has been removed (v3.4.1). These are minor housekeeping changes and do not modify the study details or user-visible trial information.SummaryDifference0.3%

- Check89 days agoChange DetectedA government funding lapse notice is now displayed, indicating the NIH site information may not be up to date and transactions may be delayed. The page revision version has been updated to v3.4.1, replacing v3.4.0.SummaryDifference0.3%

Stay in the know with updates to ABP 798 vs. Rituximab in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.